Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar-Apr;23(2):97-104.
doi: 10.1016/j.rpor.2017.12.002. Epub 2018 Feb 12.

Thymic tumors and results of radiotherapy

Sureyya Sarıhan  1 , Ahmet Sami Bayram  2 , Cengiz Gebitekin  2 , Omer Yerci  3 , Deniz Sıgırlı  4
Affiliations

Thymic tumors and results of radiotherapy

Sureyya Sarıhan et al. Rep Pract Oncol Radiother. 2018 Mar-Apr.

Abstract

Aim: The aim of this study was to evaluate thymic epithelial tumors (TETs) for treatment outcomes and prognostic factors on survival.

Background: TETs are very rare neoplasms and multidisciplinary approach is recommended according to prognostic factors.

Materials and methods: Between 1995 and 2013, 31 patients were treated with median 5400 cGy (range: 1620-6596 cGy) radiotherapy (RT). Eleven patients received adjuvant or concurrent chemotherapy. There were 25 thymomas, 4 thymic carcinomas and 2 thymic neuroendocrin carcinomas. According to Masaoka, staging and WHO classification, cases were divided to good (n: 10), moderate (n: 9) and poor (n: 12) prognostic risk groups. Survival was calculated from diagnosis.

Results: In January 2016, 22 cases were alive with median 51.5 months (range: 2-170.5) follow-up. Recurrences were observed in 29% of patients in median 29.5 months (range: 6.5-105). Local control, mean overall (OS) and disease-free survival (DFS) rates were 86%, 119 and 116 months, respectively. There was a significant difference for R0 vs. R+ resection (81% vs. 43%, p = 0.06, and 69% vs. 46%, p = 0.05), Masaoka stage I-II vs. III-IV (75% vs. 52%, p = 0.001, and 75% vs. 37%, p < 0.001), and also prognostic risk groups (100% vs. 89% vs. 48%, p = 0.003, and 100% vs. 87% vs. 27%, p = 0.004) in terms of 5-year OS and DFS, respectively.

Conclusion: In our study, prognostic risk stratification was shown to be a significant predictor of survival. There is a need to investigate subgroups that may or may not benefit from adjuvant RT.

Keywords: 3D-CRT/IMRT, three-dimensional conformal RT/intensity modulated RT; 4D-CT, four-dimensional computed tomography; CHE, chemotherapy; CT, computed tomography; DFS, disease-free survival; LC, local control; MG, Myasthenia Gravis; NEC, thymic neuroendocrin carcinoma; OS, overall survival; PET/CT, positron emission tomography; PF, prognostic factor; R+, incomplete resection; R0, complete resection; R1, microscopic residual disease; R2, macroscopic residual disease; RT, radiotherapy; TC, thymic carcinoma; TET, thymic epitelial tumor; WHO, World Health Organization; cm, centimeter.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Overall survival (OS) and prognostic factors.
Fig. 2
Fig. 2
Disease-free survival (DFS) and prognostic factors.
See this image and copyright information in PMC

References

    1. Gomez D.R., Fuller C.D., Chennupati S., Thomas C.R., Jr. Mediastinal and tracheal cancer. In: Halperin E.C., Wazer D.E., Perez C.A., Brady L.W., editors. Principles and practice of radiation oncology. 6th ed. LWW; Philadelphia: 2013. pp. 973–995.
    1. Scorsetti M., Leo F., Trama A. Thymoma and thymic carcinomas. Crit Rev Oncol Hematol. 2016;99:332–350. - PubMed
    1. http://www.nccn.org
    1. Lee H.S., Kim S.T., Lee J. A single institutional experience of thymic epithelial tumours over 11 years: clinical features and outcome and implications for future management. Br J Cancer. 2007;97:22–28. - PMC - PubMed
    1. Verghese E.T., den Bakker M.A., Campbell A. Interobserver variation in the classification of thymic tumours – a multicentre study using the WHO classification system. Histopathology. 2008;53:218–223. - PubMed